Use of a premixed insulin regimen (Novolin® 70/30) to replace self-mixed insulin regimens

S. Aronoff, R. Goldberg, D. Kumar, E. Lichtenstein, S. Schwartz, J. Sosenko

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The efficacy and safety of transferring 76 patients with poorly controlled type II diabetes mellitus from various selfmixed human insulin regimens to a premixed insulin regimen (Novolin® 70/30, 70% NPH and 30% Regular insulin, semisynthetic) were evaluated in a 24-week, multicenter, open-label study. During the initial 12-week run-in period, the patients received twice-daily doses of NPH and Regular human insulin mixed in ratios of 60/40, 80/20, 90/10, or NPH alone, as recommended by their physicians. Subsequently, these patients were transferred to a regimen of Novolin 70/30 twice daily for an additional 12 weeks. In most cases, the transfer was made on a dose-for dose basis. Following the transfer from self-mixed to premixed insulin, the mean glycated hemoglobin fell from 9.3% to 8.7% at 6 weeks (P<0.001) and to 8.5% at 12 weeks (P<0.001). This improved glycemic control was not accompanied by an increase in the frequency or severity of hypoglycemic episodes. It is concluded that patients with type II diabetes mellitus who are poorly controlled on a wide range of self-mixed insulin ratios can be safely transferred, often in a dose-for-dose fashion, to a more convenient 70/30 premixed regimen.

Original languageEnglish (US)
Pages (from-to)41-49
Number of pages9
JournalClinical Therapeutics
Issue number1
StatePublished - Jun 21 1994
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Use of a premixed insulin regimen (Novolin® 70/30) to replace self-mixed insulin regimens'. Together they form a unique fingerprint.

Cite this